SCHEMBL1333228

SCHEMBL1333228

O=C(O)CC[C@@H](C(=O)O)N1C(=O)CCC1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HPGD P15428 2/20 0.56
MAPK1 P28482 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TP53 P04637 1/20 0.56
GLA P06280 1/20 0.56
POLB P06746 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
ALOX12 P18054 1/20 0.56
NFKB1 P19838 1/20 0.56
APEX1 P27695 1/20 0.56
CYP1A2 P05177 3/20 0.55
CYP2C19 P33261 1/20 0.55
PPM1B O75688 1/20 0.54
PKM P14618 1/20 0.53
FOLH1 Q04609 5/20 0.41
TET2 Q6N021 3/20 0.39
KDM4A O75164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL631270 1.00 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDMAPK1HSD17B10
Ethylene Glycol SCHEMBL29002151 0.95 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL14674752 0.89 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDMAPK1HSD17B10
Succinic Acid SCHEMBL31137819 0.89 CYP1A2 (0.47) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL30773222 0.87 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL1226562 0.86 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL17821007 0.86 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL846234 0.86 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL4069043 0.85 CYP1A2 (0.44) ALDH1A1KDM4EHPGDMAPK1HSD17B10
SCHEMBL8510382 0.81 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119563857-A Tomato extract containing succinyl amino acid, preparation method and application thereof 北京鸿禧志业科技有限公司 2025-03-07 CN claimed
WO-2012167243-A1 COMPOSITIONS AND METHODS OF TREATMENT FOR OBESITY B & P COMPANY, INC. (US) 2012-12-06 WO claimed
EP-1443954-B1 TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES SCRIPPS RESEARCH INST (US) 2010-11-24 EP claimed
US-7399743-B2 Targeted thrombosis THE SCRIPPS RESEARCH INSTITUTE (US) 2008-07-15 US claimed
EP-1443954-A2 TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES Novartis Pharma GmbH (AT) 2004-08-11 EP claimed
US-20030194400-A1 Targeted thrombosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-10-16 US claimed
WO-2003035688-A2 TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES NOVARTIS PHARMA GMBH (AT) 2003-05-01 WO claimed
US-20250367276-A1 MICROBIOTA ANALOGS OF TUMOR ASSOCIATED ANTIGENS AND USES THEREOF ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) 2025-12-04 US disclosed
US-20250361531-A1 MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS AGAIN BIO APS (DK) 2025-11-27 US disclosed
US-20250281548-A1 ANTIMICROBIAL COMPOSITIONS COMPRISING EXTRACELLULAR VESICLES AND METHODS THEREOF WASHINGTON STATE UNIVERSITY 2025-09-11 US disclosed
US-12312627-B2 Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds GENOMATICA, INC. (US) 2025-05-27 US disclosed
CN-119563857-A Tomato extract containing succinyl amino acid, preparation method and application thereof 北京鸿禧志业科技有限公司 2025-03-07 CN disclosed
CN-119563857-A Tomato extract containing succinyl amino acid, preparation method and application thereof 北京鸿禧志业科技有限公司 2025-03-07 CN disclosed
US-7399743-B2 Targeted thrombosis THE SCRIPPS RESEARCH INSTITUTE (US) 2008-07-15 US disclosed
EP-1443954-A2 TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES Novartis Pharma GmbH (AT) 2004-08-11 EP disclosed
US-20030194400-A1 Targeted thrombosis NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-10-16 US disclosed
US-6562958-B1 Nucleotide sequences coding polypeptide for use in the treatment and prevention of infections GENOME THERAPEUTICS CORPORATION 2003-05-13 US disclosed
WO-2003035688-A2 TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES NOVARTIS PHARMA GMBH (AT) 2003-05-01 WO disclosed
EP-1144446-A1 PHARMACEUTICAL COMPOUNDS FOR THE INHIBITION OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2001-10-17 EP disclosed
WO-2000031129-A1 PHARMACEUTICAL COMPOUNDS FOR THE INHIBITION OF HEPATITIS C VIRUS NS3 PROTEASE ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) 2000-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250361531-A1 MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS HSD17B10, HSD17B12, HADHB ALDH1A1 110/4885KDM4E 374/4885HPGD 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.